19 results about "Phospholipase A2" patented technology

The invention relates to the technical field of bioengineering, in particular to a preparation process for extracting antihypertensive peptide from euphausia superba. The process comprises the following steps: adding a ferulic acid / arginine double-grafted pullulan compound in a preparation process, and breaking an emulsification interface by utilizing beta-cyclodextrin adsorption and phospholipase A2 cracking to obtain a soluble pretreatment product; meanwhile, short-time round-trip pH pulse is implemented in the incision enzyme hydrolysis process to activate potential enzyme cutting sites, finally, hydrophobic aggregation peptides are removed through weak acid rapid elution, and excision hydrolysis is performed to obtain a target product with the molecular weight of 0.5-3 kDa, so that dynamic induction and antioxidant steady-state dual control of hydrolysis reaction is realized; the generation proportion of short peptides and the ACE inhibition persistence are improved, and the flavor and the storage stability are remarkably improved. The method is controllable in technological process, high in repeatability and suitable for large-scale preparation of the euphausia superba protein functional peptide and development and application of antihypertensive food.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention relates to nucleic acid aptamers for lipoprotein-associated phospholipase A2 (Lp-PLA2), wherein the nucleic acid aptamer is at least one of B76-2, B76-4, and B76-5, with sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The Lp-PLA2 aptamers provided by this invention fill a gap in the field of Lp-PLA2 aptamers and exhibit high affinity and specificity. Three aptamers with good affinity and specificity for Lp-PLA2 have been screened and verified. These aptamers can be formulated into molecular probes or used as detection reagents in methods or kits for detecting Lp-PLA2, improving accuracy. They can also be used to develop novel Lp-PLA2 biosensing methods for molecular identification, showing great application potential in the early warning of cardiovascular disease events.

The application provides a lipoprotein phospholipase A2 determination kit for latex immunoturbidimetry, which contains reagent R1 and reagent R2; the reagent R1 comprises the following components: buffer, inorganic salt, anti-interference additive, surfactant and Proclin 300; the reagent R2 comprises the following components: buffer, lipoprotein phospholipase A2 antibody coated latex microspheres, stabilizer, surfactant and Proclin 300. The kit is a liquid kit with strong stability, high accuracy, wide linear range and strong anti-HOOK capability.

The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises cobra cardiotoxin (CDX) and a pharmaceutically acceptable carrier thereof. The pharmaceutical composition is further characterized by comprising use of cobra cardiotoxin (CDX) in combination with any one or both of the following drugs for treating migraine: cobra phospholipase A2 (PLA2) and cobra neurotoxin (NTX). The pharmaceutical composition can be used for preventing and treating migraine and down-regulating the concentration of nitric oxide (NO) in migraine patients. The pharmaceutical composition is of great significance for the treatment of migraine.

The present invention provides a biomarker for the detection of glioma microenvironment (TME), comprising a serum marker selected from any one or more of annexin A1 (ANXA1), annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2), and a pathological marker selected from any one or more of Annexin A1 (ANXA1), Annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2); the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and a phospholipase A2 group IIA (PLA2G2A), and the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and phospholipase A2 group IIA (PLA2G2A). The invention also provides an application of the biomarker in diagnosis of glioma. The invention provides an innovative idea and a biomarker for non-invasive diagnosis of glioma, and can be used for prognosis and malignant diagnosis of glioma.

The invention discloses application of a MarR family transcriptional regulation factor SCLAV2489 (GeneBank numbering EFG07562.1) or a phospholipase A2 gene SCLAV4219 (GeneBank numbering EFG09293.1) as a target in improving the fermentation yield of clavulanic acid, the MarR family transcriptional regulation factor SCLAV2489 or the phospholipase A2 gene SCLAV4219 in a streptomyces clavuliformis genome is inactivated or knocked out, so that the fermentation yield of clavulanic acid of a mutant strain can be remarkably improved, and the industrial application prospect is achieved.

The invention discloses egg yolk powder with phospholipid enzymolysis synergistic interface steady-state protection and a preparation method of the egg yolk powder, and belongs to the technical field of creation of high-quality egg yolk powder. Carrying out phospholipase A2 controllable enzymolysis pretreatment on the egg yolk liquid under the protection of nitrogen; performing micro-emulsification steady-state construction on the compound colloid of the Arabic gum and the beta-cyclodextrin; and carrying out temperature-controlled spray drying on the pretreatment liquid. The key processes are coupled to form a steady-state pretreatment scheme for actively reconstructing a lipid dispersion state from a molecular level, so that the passive defect that oxidation deterioration cannot be fundamentally inhibited due to the fact that a traditional process only depends on later packaging or external addition of an antioxidant is overcome, and the egg yolk powder with low surface free fat coverage rate (SFCR is less than or equal to 3.5%) is produced. After the product is stored for 90 days in an accelerated manner, the peroxide value growth rate (delta POV) is less than or equal to 60.0%, the key smelly aldehyde total concentration (TCKA) is less than or equal to 2.5 mu g / kg, and the emulsifying activity index retention rate is greater than or equal to 85.0%.

The invention discloses a flavoring agent for branched chain amino acid and a preparation method of the flavoring agent, and belongs to the technical field of food additives. The flavoring agent comprises a flavoring component and a composite lipid carrier coating the core component, wherein the lipid carrier is composed of phospholipid, auxiliary lipid and a structure enhancer. By introducing high-melting-point phytosterol, a soft-hard alternate microscopic phase separation structure is constructed in a flexible phospholipid bimolecular layer, on one hand, the structure provides compact physical barrier by utilizing a rigid framework formed by phytosterol, the oxidation resistance and the humidity resistance of the flavoring component are remarkably improved, and the stability of the shelf life is ensured; and on the other hand, a phospholipid region is reserved as an enzymolysis target, and the carrier is structurally disintegrated within 45 seconds when being in contact with saliva and releases the flavoring component in a pulse manner by utilizing the specific shearing action of oral cavity phospholipase A2.

The invention discloses a cardiovascular event risk index calculation method, and relates to the technical field of medical information, and the method comprises the following steps: determining whether a to-be-evaluated patient meets an application condition or not according to a preset inclusion standard; for a patient meeting the standard, collecting a peripheral blood sample of the patient, carrying out centrifugal treatment, and separating to obtain a serum or plasma sample; s2, quantitatively measuring four serological indexes, namely lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, homocysteine and serum amyloid protein A, of the serum or plasma sample obtained in the step S1 by using an authenticated laboratory detection method; s2, calculating a cardiovascular risk index by using a cardiovascular risk calculation formula based on the four index values measured in the step S2; s3, according to the cardiovascular risk index value calculated in the step S3, dividing the cardiovascular event risk of the patient into three levels of low risk, medium risk and high risk; and S4, generating a structured risk assessment report according to the risk grading result obtained in the step S4, and outputting the structured risk assessment report.

To provide a composition or the like for inhibiting infiltration of pro-inflammatory macrophages.SOLUTION: The composition comprises phospholipase A2, one of the main components of bee venom, as an active ingredient. In addition, a health functional food composition and a feed composition for inhibiting infiltration of pro-inflammatory macrophages comprising phospholipase A2 as an active ingredient are also provided.SELECTED DRAWING: Figure 1A

This invention relates to the field of monoclonal antibody technology, and in particular to a monoclonal paired antibody for lipoprotein-associated phospholipase A2 and its applications. The heavy chain sequence of the first antibody is shown in SEQ ID NO:1, and its light chain sequence is shown in SEQ ID NO:2; the heavy chain sequence of the second antibody is shown in SEQ ID NO:3, and its light chain sequence is shown in SEQ ID NO:4. The monoclonal paired antibody for lipoprotein-associated phospholipase A2 of this invention exhibits high specificity and sensitivity, providing accurate and reliable reagent support for relevant detection scenarios. It can be used in multiple detection fields, including biochemical immunoturbidimetric assays, immunochromatographic assays, and ELISA, achieving rapid, efficient, and highly sensitive clinical detection of lipoprotein-associated phospholipase A2 antigen in serum.

The invention relates to the technical field of cosmetics, and discloses a skin repair composition as well as a preparation method and application thereof. The skin repair composition is prepared from the following components in percentage by mass: 0.5 to 5 percent of herba centellae extract, 1 to 8 percent of ectoine, 1 to 3 percent of alpha-bisabolol, 0.1 to 0.5 percent of guaiacol, 0.03 to 1 percent of rhizoma curcumae longae extract, 0.2 to 0.5 percent of tetrahydrocurcumin, 0.1 to 1 percent of glycyrrhetinic acid, 0.01 to 0.2 percent of carbenoxolone sodium, 0.1 to 3 percent of ceramide, 10 to 20 percent of phospholipid, 3 to 8 percent of structured lipid MCM, 2 to 6 percent of surfactant, 15 to 30 percent of cosurfactant, 0.05 to 0.15 percent of soluble zinc salt, 0.01 to 0.1 percent of recombinant phospholipase A2 and the balance of ultrapure water. The skin repair composition disclosed by the invention can act on three levels of skin cells, epidermis and dermis, can play the effects of resisting inflammation, resisting oxidation and enhancing immunity through a multi-target action mechanism, and meanwhile, establishes a dual repair system of endogenous healing activation and external barrier reinforcement from internal and external perspectives, so that skin problems are comprehensively reduced, and the skin repair effect is improved. The skin health is obviously improved.

This invention relates to the field of biotechnology, and more particularly to a method for extracting soybean lecithin from soybean lecithin. The method includes: subjecting a first mixture of soybean lecithin and acetone to a first stirring treatment to obtain a solid crude soybean lecithin extract; subjecting a second mixture of the solid crude soybean lecithin extract and ethanol to a second stirring treatment to obtain a crude soybean lecithin extract solution; concentrating the crude soybean lecithin extract solution to obtain a concentrated solution; enzymatically hydrolyzing the concentrated solution using a complex enzyme, the complex enzyme being composed of phospholipase A2, lipase, and protease, to obtain a concentrated soybean lecithin solution; and subjecting the concentrated soybean lecithin solution to enzyme inactivation treatment and drying treatment to obtain the soybean lecithin. This method can effectively improve the yield and purity of soybean lecithin, and the extracted soybean lecithin has a high moisture retention rate, showing broad application prospects in the food industry.

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and / or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

The application discloses a method for synergistically promoting enzymatic degumming of rapeseed oil by phospholipase C and phospholipase A2, and comprises the following steps: S1, acidizing crude rapeseed oil; S2, adjusting the pH value of the acidized rapeseed oil; S3, adding phospholipase C, phospholipase A2, calcium chloride and deionized water into the system after adjusting the pH value, mixing uniformly, and then performing an enzymatic degumming reaction under a preset reaction temperature by means of ultrasonic assistance; and S4, performing enzyme inactivation treatment and centrifugal separation to obtain degummed rapeseed oil. The method adopts a phospholipase C and phospholipase A2 complex enzyme system, utilizes the catalytic complementarity of the two enzymes to different phospholipid components, breaks through the bottleneck that single enzyme cannot completely degum high-phosphorus rapeseed oil, and combines an ultrasonic auxiliary technology, so that the mass transfer efficiency of the enzyme and the substrate is strengthened through an ultrasonic cavitation effect, the degumming time is shortened, an efficient, economical and green new degumming solution is provided for the rapeseed oil refining industry, and the method has significant technical innovation and industrial application value.

To provide additional treatment options for treating cognitive impairments associated with brain disorders.SOLUTION: To provide a cytosolic phospholipase A2 ε (cPLA2e) inducer used as a medicine, especially used for treating cognitive disorders and / or diseases associated with cognitive disorders, for example, dementias, more specifically, age-related dementias and / or Alzheimer's diseases.SELECTED DRAWING: None

The invention relates to the technical field of monoclonal antibodies, in particular to a lipoprotein-associated phospholipase A2 monoclonal pairing antibody and application thereof.A heavy chain sequence of a first antibody is shown as SEQ ID NO: 1, and a light chain sequence of the first antibody is shown as SEQ ID NO: 2; the heavy chain sequence of the second antibody is as shown in SEQ ID NO: 3, and the light chain sequence of the second antibody is as shown in SEQ ID NO: 4. The lipoprotein-associated phospholipase A2 monoclonal pairing antibody disclosed by the invention has relatively high specificity and sensitivity, can provide accurate and reliable reagent support for related detection scenes, and can be applied to a plurality of detection fields such as the biochemical immunoturbidimetric detection field, the immunochromatography detection field and the ELISA (Enzyme-Linked Immunosorbent Assay) field; the rapid, efficient and high-sensitivity clinical detection on the lipoprotein-related phospholipase A2 antigen in the serum is realized.

FIELD: surgery.SUBSTANCE: used to predict the effectiveness of treatment of acute pancreatitis in the early stages. On the 1st, 4th, 7th and 11th days after hospitalization, venous blood sampling is performed from patients, the level of C-reactive protein, the activity of phospholipase A2 and alpha-amylase in the blood is assessed, and an ultrasound of the abdominal cavity is performed to identify fluid formation in the abdominal cavity. In patients with acute pancreatitis, the probability of developing complications IRO is calculated using the stated formula. With the IRO value less than 3.1 predicts high treatment effectiveness, indicating the absence of the likelihood of complications. With an IRO value from 3.2 to 4.5, average treatment effectiveness is predicted, indicating possible disease progression and development of complications and the need for constant monitoring. If the IRO value is more than 4.5, the treatment is predicted to be ineffective, indicating a high probability of complications and requiring urgent puncture interventions at the site and adjustments to treatment regimens.EFFECT: method provides the possibility of increasing the accuracy of assessing the treatment of acute pancreatitis in the early stages, predicting the course of acute pancreatitis and optimizing treatment by preventing the risk of fluid formations, due to the assessment of the state of the components of the homeostasis system: pancreatogenic, immunoinflammatory, membrane-destabilizing, and visual diagnostics of the abdominal cavity to identify fluid formations in it.1 cl, 4 tbl, 3 ex